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Abstract
Common variable immunodeﬁciency is a primary immunodeﬁciency disease characterized by reduced serum immunoglo-
bulins and heterogeneous clinical features. Recurrent pyogenic infections of upper and lower respiratory tracts are the main
clinical manifestations of common variable immunodeﬁciency. Hemolytic uremic syndrome is a multisystemic disorder
characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ ischemia due to platelet aggregation in the
arterial microvasculature. This is one of the rare cases of patients diagnosed with common variable immunodeﬁciency, which
was complicated by hemolytic uremic syndrome.
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Introduction
Common variable immunodeﬁciency (CVID) is a
disorder characterized by decreased levels of serum
immunoglobulins (IgG and IgA, and 50% of patients
have diminished levels of IgM) and an increased
susceptibility to infection (1). It is a common
form of immunodeﬁciency with a variable clinical
course. Most patients have sporadic disease, but in
the past 5 years investigators have described defects
in four genes associated with CVID (autosomal
dominant or autosomal recessive inheritance).
Park et al. have described genetic defects in a few
patients with CVID, but nearly 75% of patients have
no known defect (1,2). The prevalence of CVID is
approximately 1:50,000–200,000, with a reported
incidence of 1 per 75,000 live births (3,4). Recurrent
pyogenic infections of upper and lower respiratory
tracts are the main clinical manifestations of CVID.
These patients are more likely to have increased
frequencies of hepatosplenomegaly, iridocyclitis,
autoimmune hemolytic anemia, immune thrombo-
cytopenic purpura, malabsorption, inﬂammatory
bowel disease, failure to thrive, and autoimmune
disease (5,6).
The deﬁnition of CVID includes three key features:
the presence of hypogammaglobulinemia of two or
more immunoglobulin classes (low IgG, IgA, or
IgM), recurrent sinopulmonary infections, and
impaired functional antibody responses. The criteria
for impaired functional antibody responses include
absent isohemagglutinins, poor responses to protein
(diphtheria, tetanus) or polysaccharide vaccines
(Streptococcus pneumoniae), or both (1,3,7). Intrave-
nous immunoglobulin (IVIG) is effective and is cur-
rently the mainstay of therapy for CVID. Intravenous
immunoglobulins lower the incidence of pneumonic
and recurrent bacterial infections, thus preventing
chronic pulmonary disease (8–10). The prognosis
for patients with CVID is reasonably good. Early
diagnosis and therapy are essential in improving the
outcome in patients with CVID (11,12).
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DOI: 10.3109/03009734.2011.635815Hemolytic uremic syndrome (HUS) is primarily a
disease of infancy and early childhood and is typically
characterized by the triad of microangiopathic hemo-
lytic anemia, thrombocytopenia, and acute renal fail-
ure (13,14). Two predominant types of HUS are
identiﬁed: one type involves diarrhea (D+) (95% of
cases) and the other does not (D– or atypical). D+
HUS occurs predominantly in children and is pre-
ceded by a prodrome of diarrhea, most commonly
caused by an infection by shiga-toxin-producing
Escherichia coli.D – HUS accounts for the remaining
5% of cases of HUS, and its etiology, age at onset, and
clinical presentations are far more varied. The path-
ogenesis of D– HUS has been the focus of current
research and has, thus far, been associated with
complement dysregulation in up to 50% of cases.
Clinically, D– HUS has been associated with various
non-enteric infections, viruses, drugs, malignancies,
transplantation, pregnancy, and other underlying
medical conditions such as scleroderma and antipho-
spholipid syndrome. Infections caused by Streptococ-
cus pneumoniae have been linked to 40% of D– HUS
cases (15). Incidence of D– HUS in children is
approximately 2 cases per year per 100,000 total
population (13). Plasma exchange (plasmapheresis
combined with fresh-frozen plasma replacement) is
currently the treatment of choice. Plasma exchange is
performed daily until remission is obtained (16).
Patients with D– HUS collectively have a poor
prognosis, and as many as 50%–60% progress to
end-stage renal disease or develop irreversible brain
damage. About 25% die during the acute phase (17).
This paper reviews the case of a 5-year-old boy with
CVID complicated with HUS.
Case report
A boy, aged 5 years, had a bad cough with breathing
difﬁculties a month before hospitalization and
received out-patient treatment with antibiotics and
bronchodilators. A week before hospitalization he was
swollen in his face, he urinated less, and was
extremely dyspneic. The boy was hospitalized at
our institute, in the intensive care unit.
Since his early infancy, the boy had had repeated
bacterial respiratory infections (adenoid, middle ear,
obstructive bronchitis, and pneumonia), while at the
age of 1 he was diagnosed with generalized lymphade-
nopathy and hepatosplenomegaly. During his second
year of life, he underwent an adenoidectomy. Due to
hepatosplenomegaly, the boy had been monitored by a
hematologist between the ages of 2 and 4.5. Previous
laboratory ﬁndings: Immunoglobulins of serum IgA
0.24 g/L (0.41–2.97), IgM 0.67 g/L (0.4–1.6), IgG
5.5 g/L (6–13). Alfa 1 antitrypsin was within the
reference value. There were no indications of co-
natal and acquired virus infections, hemoglobinopathy
(fetalhemoglobin and haptoglobinwithinthe reference
values), malignant diseases (bone-marrow biopsy,
myeloid hyperplasia). The pathohistological ﬁndings
of a peripheral lymph gland sample showed reactive
lymphadenitis. In the later course, pancytopenia was
diagnosed. During the stated period, the clinical fea-
tures were dominated by obstructive pulmonary dis-
ease, and a physical examination showed splenomegaly
and generalized lymphadenopathy, accompanied by a
f a i l u r et ot h r i v e( t h eb o yh a dv e r yp o o ra p p e t i t e ,
especially during respiratory infections which he fre-
quently had). The mental status was preserved. There
were no similar diseases in the family.
At admission, the boy was in a generally difﬁcult
condition, afebrile, with tachycardia (140/min), tachy-
dyspnea (50/min), blood pressure 120/80 mmHg.
His body weight was 17 kg (below third percentile)
and his height 101 cm (below third percentile). The
skin and the visible mucous membranes were pale,
acrocyanotic, and edematous. The lymph glands were
swollen, approximately 2 cm in diameter. Pulmonary
auscultationrevealedinspiratorycrackles,earlyandlate,
with low-pitch wheezing. Heart action: gallop rhythm,
no murmur, with weaker peripheral pulses. He
had hepatosplenomegaly. Neurological ﬁndings were
normal.
Laboratory ﬁndings were as follows: increased
acute phase reactants (sedimentation rate, C-reactive
protein), pancytopenia (leukocyte count 2.7  10
9/L),
thrombocyte count 40  10
9/L; Coombs positive test,
hemolytic anemia, Hb 64 g/L, and reticulocytes 1.2%.
Osmotic resistance of red blood cells was normal.
Peripheral blood smear showed presence of frag-
mented red blood cells. Serum creatinine, 153
mmol/L (estimated creatinine clearance 30 mL/min/
1.73 m
2), urea nitrogen, 13.0 mmol/L (0.1–7),
acidum uricum, 278 mmol/L (71–230). Activated
partial thromboplastin time (aPTT), prothrombin
time (PT), D-dimer, ﬁbrinogen: normal ﬁndings.
Total serum proteins 55.5 g/L, albumin 24 g/L.
Aspartate aminotransferase, alanine aminotransfer-
ase, gamma-glutamyltransferase, bilirubin: normal
values. Cholesterol 7.28 mmol/L (up to 3), triglycer-
ides 2.22 mmol/L (up to 0.7). Blood gas analysis
indicated global respiratory insufﬁciency. Urine: pro-
tein 5+, microscopic hematuria. Hemoculture, stool
culture, urinoculture: negative. Coxsackie virus,
Cytomegalovirus, Hantaan virus (IgG and IgM): neg-
ative. Renal ultrasound: in both kidneys loss
of corticomedullary differentiation, hyperechogenic
parenchyma. Abdomen ultrasound: hepatosple-
nomegaly. Chest X-ray indicated inﬂammation and
congestive changes with enlarged heart shadow.
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opathy and pulmonary hypertension.
Immediately upon admission, mechanical ven-
tilation with parenteral antibiotic therapy was
administered (imipenem-cilastatin, clindamycin, sul-
famethoxazole/trimethoprim, and ﬂuconazole), fol-
lowed by a conservative therapy for acute renal
failure and acute pulmonary edema, and intravenous
immunoglobulin (IVIG) therapy. On the third day of
hospitalization the boy became comatose (Glasgow
Coma Scale 4–7), with focal seizures. A lumbar punc-
ture was performed to exclude infection of central
nervous system (CNS) (the ﬁndings were normal),
while computer tomography (CT) of the CNS
revealed hyperdense changes sized 2  2 cm (intra-
cerebral hematoma combined with ischemic lesions).
The diagnosed HUS (D– HUS; microangiopathic
hemolytic anemia, thrombocytopenia and acute renal
failure; the information about diarrhea was not
received) was treated with repeated transfusions of
fresh frozen plasma. The blood laboratory variables
improved. The pulmonary function and conscious-
ness were also improving; thus, on day 11, the boy was
extubated and oxygen therapy was administered
through a mask. As the acute renal insufﬁciency
progressed (creatinine 461 mmol/L, urea nitrogen
56.5 mmol/L, acidum uricum 1620 mmol/L, esti-
mated creatinine clearance 10.7 mL/min), on day
13 of hospitalization, a continuous ambulatory peri-
toneal dialysis (CAPD) was started. This led to some
improvement in renal function test results and further
improvement of consciousness, as well as the general
condition, so the boy was transferred to the nephrol-
ogy ward. In order to arrive at a ﬁnal diagnosis,
tests were continued to determine immunological
disorders—immunoglobulin deﬁciency and immuno-
logical response, systemic disease (due to purpura
on the trunk, vasculitis; and sclerodermatous-like
changes on the right gluteus, 5  10 cm, and on
the right lower leg, 5  3 cm, which were not present
initially): antinuclear antibodies (ANA), anti-double
stranded DNA, anti-RNP, anti-Sm, anti-SSA/Ro,
anti-SS-B/La, anti-Scl-70, anti-Jo-1, anti-cardiolipin
antibodies (ACA), antineutrophil cytoplasmic antibo-
dies (ANCA), antimitochondrial antibodies, anti-
parietal antibodies, anti-smooth muscle antibodies,
antiheart antibodies, and antithyroid antibodies: neg-
ative. Pathohistological examination of skin samples
was non-speciﬁc and excluded scleroderma. IgA
0.16 g/L (0.41–2.97), IgG 3.3 g/L (6–13), IgM
0.13 g/L (0.4–1.6); all three classes of immunoglob-
ulin were lowered in the three samples taken at
monthly intervals. The antitetanus antibody titer
was at the lower limit of the normal range. The
nitroblue tetrazolium (NBT) test, opsonization, and
bactericidal index were normal. Immunophenotyp-
ing: relative, absolute values of total T lymphocytes
(CD3), as well as CD4 and CD8 subpopulation of
T lymphocytes, were within physiological limits, with
a preserved ratio (index CD4/CD8). Relative and
absolute values of B lymphocytes (CD19), as well
as NK cells (CD56), were within physiological limits.
Immune complexes (PEG-198) and complement
C1q, C3, and C4 had normal values. Blastic trans-
formation of lymphocytes in culture stimulated by
phytohemagglutinin (PHA) showed high spontaneous
activity. Isohemagglutinins were negative.
DuodenaljuicewasfreeofGiardialamblia.Amicro-
scopic stool examination revealed cysts of non-
pathogenic ameba. A sweat chloride test was negative.
Siderophages in bronchial aspirate was negative. CT
scan of chest and abdomen showed enlarged thymus
and mediastinal and retroperitoneal glands.
When suspicion of CVID was raised, a substitution
therapy was introduced: IVIG (600 mg/kg per 3–4
weeks) with additional supportive therapy. Because
autoimmune phenomena were present, he received
corticosteroids during 1 month (prednisone 0.5 mg/
kg). In the course of the therapy, the boy did not have
respiratory infections; signs of chronic pulmonary dis-
ease were persistent; hemoglobin, leukocytes, and
thrombocyteswerenormalized;andautoimmunephe-
nomena were in complete regression. Consciousness
and mental status were completely restored. A control
CTscanofthe CNS showedporencephalic changesin
the place of the previously described lesions. After
3 months, peritoneal dialysis was discontinued,
chronic renal insufﬁciency persisted (estimated creat-
inine clearance 35.0 mL/min/1.73 m
2).
Atthebeginning,thediagnosisofCVIDwasdifﬁcult
due to numerous complications and a slightly
decreased level of immunoglobulin at the time of ﬁrst
medical check-up in the second year of life (levels of
immunoglobulin in CVID may vary). During the ﬁrst
3 months of treatment he was on renal replacement
therapy (peritoneal dialysis) followed by 1 month of
corticosteroid therapy, which also could lead to reduc-
tion in serum immunoglobulin levels. The cause of the
loss of immunoglobulins, at the beginning of the
disease, could be proteinuria, i.e. nephrotic syndrome
as manifestation of HUS. However, in the further
course, when he was not subjected to the above-
described therapies, and when the proteinuria signif-
icantly decreased (to 470 mg/24 h; dipstick proteinuria
test 2–3+), with the normalization of serum albumin,
low levels of immunoglobulins still persisted (IgA0.16,
0.36, and 0.2 g/L; IgM 0.13, 0.12, and 0.5 g/L; IgG
3.3, 3.0, and 2.9 g/L). Based on repeated analyses of
immunoglobulin and the persistently low levels, the
clinical features being frequent respiratory infections
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bronchiectasis), growth retardation, failure to thrive,
myocardiopathy, hepatosplenomegaly, autoimmune
phenomena (similar to scleroderma), as well as nega-
tive isohemagglutinins and poor response to active
immunization (tetanus toxoid), the diagnosis of
CVID was established.
After 1 year, due to irregular substitution therapy
by immunoglobulin, febrile respiratory infections
recurred. As the chronic pulmonary disease pro-
gressed, the boy was on a home oxygen therapy.
A year and a half after the basic disease had been
diagnosed, the boy suddenly died during a bicycle
ride, most probably due to cardiorespiratory insufﬁ-
ciency (the parents did not allow an autopsy).
Discussion
CVID is one of the most prevalent primary immuno-
deﬁciency diseases. The age at presentation of CVID
has a bimodal distribution. A few patients present in
mid-childhood, but most present in early to mid-
adulthood (1).
One-third of these patients develop diffuse or local-
ized lymphadenopathy, intestinal nodular hyperpla-
sia, or lymphoid inﬁltrates in the lung. Histologically,
these inﬁltrates resemble the reactive lymphoid hyper-
plasia. The lungs are the most commonly affected site
with multisystemic granulomas, though other organs,
such as liver, skin, spleen, and gastrointestinal tract,
can also be involved (18,19).
Some 25% of patients with CVID have autoim-
mune events—autoimmune thrombocytopenic pur-
pura, autoimmune hemolytic anemia, pernicious
anemia, autoimmune thyroiditis, rheumatoid arthri-
tis, vitiligo, and vasculitis (1,6).
Chronic pulmonary complications, including
recurrent pneumonia, are the primary causes of sig-
niﬁcant morbidity in patients with CVID. Pulmonary
ﬁbrosis and bronchiectasis occur frequently. In over
50% of patients with CVID chronic bronchitis and
asthma are also recorded (20).
In the ﬁrst place, the differential diagnosis included
macrophage activation syndrome (MAS). It is char-
acterized by uncontrolled hyperinﬂammation on the
basis of inherited or acquired immune-mediated pro-
cesses in which excessive activation and non-
malignant proliferation of activated macrophages
are observed. MAS can be included in the group
of histiocytic disorders named ‘hemophagocytic
lymphohistiocytosis’ (HLH). HLH can be primary
or secondary. The secondary form can be caused
by infection (mostly viruses, but also bacteria, proto-
zoa, and fungi), malignancy (especially lymphomas),
or autoimmune disease (MAS).
MAS is a severe, potentially life-threatening, com-
plication of several chronic rheumatic diseases of
childhood. It occurs most commonly with systemic-
onset juvenile idiopathic arthritis (21,22). The diag-
nosis of MAS requires that ﬁve out of eight criteria be
fulﬁlled. First, there are the ﬁve initial criteria: 1)
fever; 2) cytopenia; 3) splenomegaly; 4) hypertrigly-
ceridemia and/or hypoﬁbrinogenemia; and 5) hemo-
phagocytosis. Then there are three recent criteria: 6)
low or absent NK cell activity; 7) hyperferritinemia;
and 8) high plasma levels of soluble CD25 (23–25).
First-line treatment for MAS is parenteral adminis-
tration of high-dose corticosteroids. Steroid-resistant
cases require the addition of cyclosporine A. Other
therapeutic regimens are high-dose IVIG, antithymo-
cyte globulins, etanercept, etoposide, and plasmaphe-
resis (24).
In our patient, speciﬁed criteria such as cytopenia,
splenomegaly, and hypertriglyceridemia were present
(hypertriglyceridemia was understood as a manifes-
tation of nephrotic syndrome within HUS; with the
reduction of proteinuria and correction of serum
albumin level, normalization of serum triglyceride
level followed). Ferritin and plasma levels of soluble
CD25, as well as bone-marrow biopsy, were not
analysed due to technical reasons. Nevertheless, our
patient fulﬁlled few clinical and laboratory criteria for
the diagnosis of MAS. After the recovery from gen-
eralized bacterial infection, and courses of immuno-
globulin replacement therapy, there was a rapid
recovery of the boy’s general condition (he received
short-term low-dose corticosteroid therapy when his
general condition was already signiﬁcantly improved).
Retrospectively, such a clinical scenario favors our
suspicion that it probably was CVID, not MAS.
At admission, the boy already had complications—
chronic pulmonary disease with pulmonary hyper-
tension, and consequential myocardiopathy, hepa-
tosplenomegaly, lymphadenopathy, autoimmune
phenomena, malabsorption, growth retardation, and
failure to thrive. The likely diagnosis of CVID was
based on the following criteria: frequent bacterial
infections (consequently leading to advanced chronic
pulmonary disease and bronchiectasis), growth
retardation and failure to thrive, myocardiopathy,
hepatomegaly, autoimmune phenomena (similar to
scleroderma), decreased levels of IgG, IgA, and IgM,
absence of isohemagglutinin synthesis, and poor
response to active immunization (tetanus toxoid).
The heterogeneity in the clinical presentation of
CVID presents a challenge to doctors. A deﬁnite
diagnosis is often late because it is wrongly assumed
that primary immunodeﬁciencies are extremely rare,
hence many patients are already seriously ill at the
time of presentation (7).
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224 patients with CVID, with 75% of them under
14 years of age. The mean age at the time of diagnosis
was 26.6 years. The mean age at the onset of symp-
toms was 16.9 years. This suggests a mean diagnostic
delay of 8.9 years. Respiratory tract infections were
the most prominent clinical problem (26).
Kidney problems are not commonly associated
with CVID. An acute renal failure from IVIG therapy
has been described as well as a nephrotic syndrome
from secondary amyloidosis, a steroid-responsive
nephrotic syndrome, and kidney dysfunction from
granulomatous interstitial nephritis (27).
The clinical pathway of CVID in our patient was
complicated with the development of HUS, which
probably developed from a bacterial infection. The
current outcomes of HUS have improved signiﬁcantly
with the use of plasma exchange, but the mortality
remains unacceptably high at 10%–25% (17,28).
This is one of the rare cases of patients diagnosed
with CVID which was complicated with HUS. The
reason for the fatal outcome in our patient’s case was
the belated CVID diagnosis with numerous compli-
cations—primarily the signs of advanced chronic pul-
monary disease with consecutive cardiomyopathy.
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